Efforts to refine therapy have reduced the mortality rate and increased the organ preservation rate in patients with head and neck cancer during the past five years. Further, improvement in therapy outcome would result from identification of biological markers that can predict the probabilities would respond to different therapy modalities. Such an achievement would make it possible to select the best therapy for individual patients based on their distinct tumor features. One potential marker is epidermal growth factor receptor (EGFR), a transmembrane glycoprotein with an intracellular domain possessing intrinsic tyrosine kinase activity. The marker is over-expressed in many tumors including the vast majority of head and neck carcinomas. Emerging data, mostly from in vitro studies, suggest an association between extent of EGFR over-expression and resistance to some cytotoxic drugs and radiation. Preliminary evidence linking EGFR over- expression and poor relapse-free and overall survival has also been reported. The validity of these interesting leads has not, however, been established in a sufficiently large, well-characterized patient population receiving consistent therapy. We propose to identify correlations between EGFR level and clinical outcome in 973 patients with stage III and IV head and neck carcinomas enrolled in a prospective randomized trial of Radiation Therapy Oncology Group. The original study was designed to assess the relative efficacy of four radiation fractionation regimens. Since treatment consisted of radiotherapy only in all patients, the study population is ideal for addressing the value of EGFR expression in predicting tumor response to radiotherapy in general and to altered fractionation regimens, particularly accelerated fractionations. Biopsy samples and follow-up data are available for these patients. We hope to find a method for identify patients with tumors most likely to respond to radiotherapy so that only those with radio-resistant tumors would be subjected to extensive surgery and its attendant morbidity.
Our specific aims are as follows: 1) define the range and distribution of EGFR protein expression in stage III and IV head and neck carcinomas; 2) determine the potential association between EGFR expression and clinical prognostic factors and other biomarkers; 3) test a hypothesis that the basal EGFR expression level is an independent prognostic indicator for local-regional control of stage III & IV head and neck cancer treated with radiotherapy alone; 4) test a second hypothesis that the basal EGFR expression level is positively correlated with the extent of in vivo tumor clonogen proliferation during the course of radiotherapy; and 5) assess whether the addition of EGFR expression level is positivity correlated with the extent of in vivo tumor clonogen proliferation during the course of radiotherapy; and 5) assess whether the addition of EGFR expression level imposes risk assessment by RTOG's recursive partitioning analysis had hence refines patient stratification in future trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084415-02
Application #
6350421
Study Section
Radiation Study Section (RAD)
Program Officer
Wu, Roy S
Project Start
2000-02-07
Project End
2003-01-31
Budget Start
2001-03-22
Budget End
2002-01-31
Support Year
2
Fiscal Year
2001
Total Cost
$179,759
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Radiation-Diagnostic/Oncology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Chung, Christine H; Zhang, Qiang; Hammond, Elizabeth M et al. (2011) Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 81:331-8
Thariat, Juliette; Milas, Luka; Ang, K Kian (2007) Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 69:974-84
Wang, Huijun; Zhang, Zhengdong; Li, Ruiyun et al. (2005) Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer 116:285-90
Ang, K Kian; Andratschke, Nicolaus H; Milas, Luka (2004) Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 58:959-65
Nakata, Eiko; Hunter, Nancy; Mason, Kathy et al. (2004) C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 59:1163-73
Liang, Ke; Ang, K Kian; Milas, Luka et al. (2003) The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57:246-54
Milas, L; Mason, K A; Ang, K K (2003) Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings. Int J Radiat Biol 79:539-45
Ang, K Kian; Berkey, Brian A; Tu, Xiaoyu et al. (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-6
Hassan, Khaled A; Ang, K Kian; El-Naggar, Adel K et al. (2002) Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 62:6414-7